Home Alzheimer’s Disease Laurent Levy and Tanguy Lim-Seiwert, MD, on the Potential of NBTXR3 to...

Laurent Levy and Tanguy Lim-Seiwert, MD, on the Potential of NBTXR3 to Treat Patients With Head and Neck Cancers

CancerNetwork® spoke with the CEO of Nanobiotix and an assistant professor of Oncology at John Hopkins Medicine to learn more regarding the potential of the radio enhancer NBTXR3.

CancerNetwork® spoke with Laurent Levy, CEO of Nanobiotix, and Tanguy Lim-Seiwert, MD, of John Hopkins Medicine, to discuss the potential of NBTXR3, a radio enhancer designed to destroy tumors through physical cell death when activated by radiotherapy.

“We started this company with the idea that, instead of using chemistry or biology to treat cancer, maybe we should try another path,” explained Levy. “That’s why we decided to use physics, and we decided to bring physics into the cell to make sure we can have a treatment that could benefit millions of patients. That’s what led us to invent NBTXR3.”

The agent provided positive results in a number of trials including the phase 3 NANORAY-312 trial,…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Lower-Dose Hypofractionated Radiotherapy Schedule Proves Effective for Patients With Locally Advanced Bladder Cancer

Using a hypofractionated schedule of 55 Gy in 20 fractions over 4 weeks to treat patients with locally advanced bladder cancer was noninferior to...

Study Identifies New Biomarker Which Could Predict Response to CD40 Immunotherapy in Pancreatic Cancer

Research published in JCI Insight identified systemic inflammation as a possible resistance mechanism to a CD40–based chemoimmunotherapy in patients with advanced pancreatic cancer.1According to...

Significant Interfacility Variation Found in Implementation of Low-Value Breast Cancer Procedures

A number of facility-level characteristics were associated with the use of low-value breast cancer procedures, and interfacility variation presented an opportunity for formal de-implementation...

KarMMa Trial Results for Ide-Cel in Refractory Myeloma Show Favorable Efficacy

Chimeric antigen receptor (CAR) T-cell therapy with idecabtagene vicleucel (ide-cel) induced responses in almost 75% of patients with multiple myeloma following relpase on multiple...

Recent Comments